Adriana D. Benavides
Immunologist who worked at UT Health San Antonio and the Children's Hospital of Philadelphia, and a co-author of the first small safety trial of rapamycin in healthy older people
Department of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio (at the time of the study, 2018) · Infectious Disease Research Division, Children's Hospital of Philadelphia (papers 2015–2016)
Portrait: UT Health San Antonio, The Pipette Gazette
Adriana Benavides is a co-author of KRA2018, a small trial in San Antonio that asked a basic question before any longevity trial: is daily rapamycin safe for healthy older people? In this randomised pilot trial, 25 people aged 70 to 95 were followed for eight weeks or more. The drug was well tolerated, with only minor changes in red blood cells, and in this short window it did not raise blood glucose or cause insulin resistance, a side effect seen with daily rapamycin in mice. The trial was too small and too short to measure any effect on aging itself, but it laid groundwork for larger studies such as PEARL.
PubMed links Benavides to rapamycin and immune research in San Antonio and Philadelphia. Benavides co-authored a 2012 Aging Cell study from San Antonio showing that lifelong rapamycin improved age-related memory problems in mice, a 2015 review on how invariant natural killer T cells, a type of immune cell, attack tumours (Children's Hospital of Philadelphia), and a 2016 paper on how mice adapt to long-term rapamycin, which lists both institutions. No current position could be confirmed, so the affiliation shown is the one on the Atlas paper.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2018 | H | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. KRA2018 Co-author of this pilot trial, which tracked immune, metabolic and other safety measures in older adults taking rapamycin. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Adriana D. Benavides.
ShowHide
- Dean L. Kellogg Jr. A geriatrician who co-leads clinical trials of rapamycin in older adults at the Barshop Institute, with a focus on safety and cardiovascular effects.
- Ellen Kraig Immunologist at UT Health San Antonio who studies how aging changes immune regulation and who led the first small safety trial of rapamycin in healthy older people at the Barshop Institute
- Martin A. Javors Pharmacologist and professor at UT Health San Antonio who directs an analytical laboratory for biochemical and drug measurements, and a co-author of rapamycin studies in mice and in older people
- Nicolas Musi Endocrinologist and aging researcher who directs the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Aging Center at Cedars-Sinai, and who studies how aging drives insulin resistance, frailty and senescence
- Qianqian Liu Biostatistician on one of the first randomised pilot trials of rapamycin's safety in older adults
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.